Compare Recursion Pharmaceuticals Inc (RXRX) vs Visa Inc (V) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Visa Inc — how do they compare? Recursion Pharmaceuticals Inc trades at $3.99 (market cap $2.31B), while Visa Inc trades at $374.9 (market cap $698.56B). The key difference: Visa Inc is far larger — about 302.4× Recursion Pharmaceuticals Inc's market cap, and Visa Inc pays a 0.72% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Recursion Pharmaceuticals Inc for 22 Days and Visa Inc for 115 Days on average.
| RXRX | V | |
|---|---|---|
Market Cap | $2.31B | $698.56B |
Volume | 40,478,768 | 4,446,146 |
Sector | Health | Financials |
52-Week High | $6.79 | $384.14 |
52-Week Low | $2.84 | $295.52 |
Typical Hold Time | 22 Days | 115 Days |
Enterprise Value | $1.83B | $709.14B |
Dividend Yield | — | 0.72% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $4.27, down 7.78% today, with a bullish technical signal from moving averages but negative profitability. The company reported a net loss of -$644.76M in 2025, with revenue of $74.26M, and has beaten earnings estimates in two of the last three quarters. Recent news highlights strategic AI partnerships and pipeline expansion, though financial performance remains challenged.
The outlook is mixed: analyst consensus is 40% buy, 60% hold, with no sell ratings, indicating cautious optimism for long-term AI-driven growth. Key risks include persistent cash burn, high valuation multiples, and slow revenue growth. Upside depends on successful drug development and partnership milestones, but near-term profitability remains elusive.
Visa (V) trades at $375.10, up 1.2% today, with a bullish technical outlook and strong fundamentals. The stock shows robust revenue growth, with 2025 revenue reaching $40 billion and net income of $20.06 billion, supported by high profitability margins. Recent earnings beats and a consensus analyst price target of $422.24 reflect positive sentiment, while news highlights AI integration and stablecoin partnerships as growth catalysts.
The outlook for Visa remains favorable, driven by earnings momentum and strategic initiatives in digital payments. Key risks include competitive pressures from fintech and regulatory scrutiny, but institutional ownership trends and a dominant market position underpin long-term potential. The stock offers upside based on analyst targets, though investors should monitor execution on AI and payment innovation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Visa Inc
Visa Inc. operates a retail electronic payments network and manages global financial services. The Company also offers global commerce through the transfer of value and information among financial institutions, merchants, consumers, businesses, and government entities.
Read more on V →
